Cargando…

Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model

Medullary thyroid carcinoma (MTC) is a tumor deriving from the thyroid C cells. Vandetanib (VAN) and cabozantinib (CAB) are two tyrosine kinase inhibitors targeting REarranged during Transfection (RET) and other kinase receptors and are approved for the treatment of advanced MTC. We aim to compare t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carra, Silvia, Gaudenzi, Germano, Dicitore, Alessandra, Saronni, Davide, Cantone, Maria Celeste, Plebani, Alice, Ghilardi, Anna, Borghi, Maria Orietta, Hofland, Leo J., Persani, Luca, Vitale, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002338/ https://www.ncbi.nlm.nih.gov/pubmed/33809722 http://dx.doi.org/10.3390/ijms22063031

Ejemplares similares

Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer
por: Saronni, Davide, et al.
Publicado: (2022)

Modeling Lung Carcinoids with Zebrafish Tumor Xenograft
por: Carra, Silvia, et al.
Publicado: (2022)

Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study
por: Dicitore, Alessandra, et al.
Publicado: (2023)

Long-term effects of somatostatin analogues in rat GH-secreting pituitary tumor cell lines
por: Dicitore, A., et al.
Publicado: (2021)

Synergistic activity of everolimus and 5‐aza‐2′‐deoxycytidine in medullary thyroid carcinoma cell lines
por: Vitale, Giovanni, et al.
Publicado: (2017)

Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension
por: Milling, Rikke Vilsbøll, et al.
Publicado: (2018)

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
por: Højer Wang, Linnea, et al.
Publicado: (2023)

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
por: Degrauwe, Nils, et al.
Publicado: (2012)

Role of vandetanib in the management of medullary thyroid cancer
por: Brassard, Maryse, et al.
Publicado: (2012)

Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms
por: Cella, Chiara Alessandra, et al.
Publicado: (2023)

Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms
por: Cantone, Maria Celeste, et al.
Publicado: (2021)

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
por: Fallahi, Poupak, et al.
Publicado: (2019)

Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study
por: Faggiano, A, et al.
Publicado: (2012)

Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
por: Grande, Enrique, et al.
Publicado: (2013)

Vandetanib
por: Vozniak, J. Michael, et al.
Publicado: (2012)

Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy
por: Lodish, Maya, et al.
Publicado: (2015)

Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience
por: Kim, Mijin, et al.
Publicado: (2020)

Phototoxic drug eruption induced by vandetanib used for the treatment of metastatic medullary thyroid cancer()
por: Bostan, Ecem, et al.
Publicado: (2022)

Cabozantinib for progressive metastatic medullary thyroid cancer: a review
por: Colombo, Joshua R, et al.
Publicado: (2014)

Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment
por: Werner, R.A., et al.
Publicado: (2015)

Effect of Vandetanib Treatment on Cystic Changes in the Liver following Metastasis from Medullary Thyroid Carcinoma
por: Matsui, Ai, et al.
Publicado: (2022)

Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer
por: Hart, Christopher D, et al.
Publicado: (2013)

Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
por: Kapur, Sakshi, et al.
Publicado: (2014)

Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment: Erratum
Publicado: (2016)

Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer
por: Del Rivero, Jaydira, et al.
Publicado: (2018)

Crucial role of zebrafish prox1 in hypothalamic catecholaminergic neurons development
por: Pistocchi, Anna, et al.
Publicado: (2008)

Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial
por: Kreissl, Michael C., et al.
Publicado: (2020)

Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy
por: Colombo, Carla, et al.
Publicado: (2018)

Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib
por: Jáklová, Kateřina, et al.
Publicado: (2021)

Vandetanib induces a marked anti-tumor effect and amelioration of ectopic Cushing’s syndrome in a medullary thyroid carcinoma patient
por: Bseiso, Hashem, et al.
Publicado: (2016)

Epigenome-wide association study in hepatocellular carcinoma: Identification of stochastic epigenetic mutations through an innovative statistical approach
por: Gentilini, Davide, et al.
Publicado: (2017)

Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis
por: Trimboli, Pierpaolo, et al.
Publicado: (2018)

Stevens-Johnson Syndrome Induced by Vandetanib
por: Yoon, Jimi, et al.
Publicado: (2011)

Radiosensitisation of Hepatocellular Carcinoma Cells by Vandetanib
por: Znati, Sami, et al.
Publicado: (2020)

Jagged Ligands Enhance the Pro-Angiogenic Activity of Multiple Myeloma Cells
por: Palano, Maria Teresa, et al.
Publicado: (2020)

Volumetric and texture analysis of pretherapeutic (18)F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib
por: Werner, Rudolf A., et al.
Publicado: (2018)

Selective use of vandetanib in the treatment of thyroid cancer
por: Fallahi, Poupak, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_20erl4rg01p0p5ih7ltvks8m5s